

The Intersection of Substance Use and Psychiatric Disorders: A Dual Diagnosis Perspective

¹Kamran Safdar, ²Dr farukh Akhtar, ³Dr Ghulam Shabir Shaikh, ⁴Muhammad Sadiq Achakzai, ⁵Dr Muhammad Tarique Arain, ⁶Babar Shahzad

Submission: 20 January 2026 | **Acceptance:** 11 February 2026 | **Publication:** 10 March 2026,

¹Mayo Hospital Lahore/King Edward Medical University Lahore

²CMH Kharian Medical college, Kharian

³ Sir C.J Institute of Psychiatry and Behavioral Science, Hyderabad

⁴AssociateProfessor, Gastroentrolology, Bolon Medical College

⁵Assistant professor Psychiatry Dow university health science karachi.

⁶Liaqat Hospital, Karachi

Abstract

Background:

Substance use and psychiatric disorders often coexist, creating complex clinical presentations and posing significant challenges to treatment and recovery. This phenomenon, known as dual diagnosis or co-occurring disorders, is increasingly recognized as a critical issue in mental health and addiction services.

Objective:

To explore the relationship between substance use and psychiatric disorders, focusing on prevalence, patterns, diagnostic difficulties, and integrated treatment outcomes.

Methods:

This cross-sectional study analyzed medical records of 500 patients from mental health and substance abuse treatment centers. Patients were evaluated for comorbid psychiatric and substance use disorders using standardized diagnostic tools.

Results:

Findings revealed high comorbidity rates, with mood and anxiety disorders being the most common among substance users. Integrated treatment programs showed better adherence and symptom reduction compared to separate treatments.

Conclusion:

Dual diagnosis demands an integrated and multidisciplinary treatment approach. Early identification, tailored interventions, and coordinated care are essential for improving long-term outcomes.

Keywords: Multifactorial, important, identification, psychiatric disorder

Introduction

The comorbidity of substance uses and psychiatric disorders has emerged as a pressing concern in both clinical and public health domains [1]. This intersection, commonly referred to as dual diagnosis, reflects a condition wherein individuals experience both a substance use disorder and a co-occurring psychiatric illness such as depression, anxiety, bipolar disorder, or schizophrenia [2]. While either condition is challenging on its own, their coexistence compounds the complexity of diagnosis, management, and recovery. Research indicates that individuals with mental health disorders are more likely to use

substances as a form of self-medication, aiming to alleviate emotional distress, hallucinations, or social withdrawal [3]. Conversely, chronic substance use can precipitate or exacerbate psychiatric symptoms, creating a bidirectional and self-perpetuating cycle. Studies show that nearly 50% of individuals with a severe mental disorder also experience substance abuse at some point in their lives [4]. From a clinical perspective, the dual diagnosis population is often underdiagnosed and undertreated. Fragmentation of care, with mental health and addiction services operating in silos, has led to ineffective management and increased morbidity [5]. Patients with dual disorders also exhibit higher rates of hospitalization, homelessness, incarceration, and suicide compared to those with a single diagnosis [6]. Early recognition and intervention are paramount. Integrated treatment where psychiatric and substance use disorders are addressed simultaneously by a coordinated care team has shown promise in improving adherence, reducing symptoms, and enhancing functional outcomes [7]. However, barriers such as stigma, lack of resources, and inadequate training persist. This study seeks to investigate the prevalence and patterns of co-occurring psychiatric and substance use disorders in a clinical population, evaluate diagnostic challenges, and assess treatment outcomes in integrated vs. non-integrated care models [8]. By understanding the dynamics of dual diagnosis, we aim to inform more effective and compassionate approaches to care.

Methodology

This cross-sectional observational study was conducted at three urban mental health and addiction treatment centers over a period of one year (January–December 2024). A total of 500 adult patients aged 18–65 years were recruited using purposive sampling. Inclusion criteria included a confirmed diagnosis of either a psychiatric disorder or a substance use disorder, with or without co-occurrence. Patients with cognitive impairments preventing informed consent were excluded. Data were collected through structured clinical interviews based on DSM-5 criteria, supplemented by the Mini-International Neuropsychiatric Interview (MINI). Substance use patterns were assessed using the Addiction Severity Index (ASI), while psychiatric symptom severity was measured using the Brief Psychiatric Rating Scale (BPRS). Treatment modalities integrated or separate were documented, and clinical outcomes such as treatment adherence, symptom reduction, and relapse rates were analyzed. Descriptive and inferential statistics were applied using SPSS v26.

Results

Analysis revealed that 58% of the sample (n=290) had co-occurring psychiatric and substance use disorders. Among them, depressive disorders (34%), generalized anxiety disorder (26%), and schizophrenia (18%) were most common. Alcohol (45%) and cannabis (27%) were the most frequently abused substances. Patients receiving integrated treatment (n=160) showed significantly higher adherence rates (78%) compared to those in non-integrated settings (n=130, adherence 49%). Symptom improvement was also more marked in the integrated group across both psychiatric and substance use parameters.

Table 1: Prevalence of Psychiatric Disorders in Substance Users (n=290)

Psychiatric Disorder	Number of Patients	Percentage (%)
Major Depressive Disorder	99	34%
Generalized Anxiety	75	26%
Schizophrenia	52	18%
Bipolar Disorder	37	13%

Psychiatric Disorder	Number of Patients	Percentage (%)
PTSD	27	9%

Table 2: Treatment Outcomes in Integrated vs. Non-Integrated Programs

Outcome	Integrated Care (n=160)	Non-Integrated Care (n=130)
Treatment Adherence (%)	78%	49%
Symptom Reduction (mean BPRS score)	12-point reduction	7-point reduction
Relapse within 6 months (%)	22%	38%

Discussion

The findings of this study highlight the substantial burden of dual diagnosis in clinical settings and emphasize the pressing need for integrated treatment approaches [9]. Over half of the participants were found to have both a psychiatric and a substance use disorder, reinforcing previous evidence of high comorbidity [10]. These patients often represent some of the most vulnerable individuals within the healthcare system, frequently cycling between emergency rooms, psychiatric wards, and rehabilitation centers. The high prevalence of depressive and anxiety disorders in individuals with SUD points to the likely role of substances as coping mechanisms [11]. Alcohol, for instance, is frequently used to mitigate feelings of sadness or anxiety, while cannabis may serve to dull psychotic symptoms or insomnia. However, this temporary relief is followed by exacerbated psychiatric symptoms over time, reinforcing a destructive cycle that is difficult to break without professional intervention. A key strength of this study is the comparative evaluation of integrated versus non-integrated treatment models [12]. Our results clearly show that patients in integrated care settings had better adherence, more significant symptom reduction, and lower relapse rates. These outcomes underscore the benefits of a coordinated approach, where both mental health and addiction professionals work together to develop comprehensive and personalized treatment plans [13]. Despite these benefits, access to integrated care remains limited in many regions due to funding constraints, lack of trained personnel, and persistent institutional divides between mental health and addiction services. Moreover, stigma associated with dual diagnosis can prevent individuals from seeking help or disclosing their symptoms honestly [14]. The need for early detection and continuous monitoring is critical. Routine screening for substance use in psychiatric settings, and vice versa, can aid in timely diagnosis and tailored interventions. Furthermore, training healthcare providers to manage dual diagnosis and fostering collaboration between service sectors are essential steps toward closing the care gap [15]. Ultimately, tackling dual diagnosis requires more than just clinical solutions. Addressing the social determinants of health such as housing, employment, and social support must be part of a holistic strategy. By adopting integrated, patient-centered models and dismantling barriers to access, we can significantly improve outcomes for those navigating the complex interplay of psychiatric illness and substance use.

Conclusion

Substance use and psychiatric disorders often exist in a reciprocal relationship, compounding individual suffering and complicating clinical care. This study reaffirms the high prevalence of dual diagnosis and demonstrates the clear advantages of integrated treatment over fragmented care. To effectively address this intersection, mental health and addiction services must move toward collaborative, multidisciplinary models that prioritize early intervention, individualized care, and societal support. Enhanced awareness,

resource allocation, and policy integration are pivotal in transforming the outcomes for this high-risk population.

Reference:

1. Sweileh, W. M. (2024). Research landscape analysis on dual diagnosis of substance use and mental health disorders: key contributors, research hotspots, and emerging research topics. *Annals of General Psychiatry*, 23(1), 32.
2. Chiappini, S., Gramuglia, P. D., Mosca, A., Cavallotto, C., Miuli, A., Corkery, J. M., ... & Martinotti, G. (2024). Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review. *Frontiers in Psychiatry*, 15, 1508732.
3. Ahmad, N., Zainal, N., Shamsu, L. S., & Zamri, Z. H. (2024). Challenges of the Insanity Defence: Legal Perspectives on Mental Illness and Criminality in Brunei's Dual Legal System. *Manchester Journal of Transnational Islamic Law & Practice*, 20(4).
4. Carr, E. R. (2025). Bridging the gap of inequity in implementation science: Adaptations of Group EBPs for those with Serious Mental Illness in the Public Sector. *Community Mental Health Journal*, 61(4), 639-648.
5. Modeste-James, A., Fitzgerald, T., Stewart, E., De Jesus, D., Canuto, M., Guzman, M., ... & Lundgren, L. (2024). The intersections between sexual orientation, Latine ethnicity, social determinants of health, and lifetime suicide attempts in a sample being assessed for entry to co-occurring mental health and substance use disorder treatment. *Journal of Primary Care & Community Health*, 15, 21501319241240425.
6. Cavallotto, C., Chiappini, S., Mosca, A., d'Andrea, G., Di Carlo, F., Piro, T., ... & Martinotti, G. (2024). Examining lurasidone efficacy in patients with schizophrenia spectrum illness and concurrent alcohol and substance use disorder: a prospective, multicentric, real-world investigation. *Journal of Clinical Medicine*, 13(8), 2206.
7. Ricci, V., Ciavarella, M. C., Marrangone, C., Messas, G., Maina, G., & Martinotti, G. (2025). Modern perspectives on psychoses: dissociation, automatism, and temporality across exogenous and endogenous dimensions. *Frontiers in Psychiatry*, 16, 1543673.
8. Sharp, A., Sorokopud-Jones, M., Haworth-Brockman, M., Kasper, K., MacKenzie, L., Ireland, L., ... & Rueda, Z. V. (2024). Sex differences in houselessness, injection drug use, and mental health conditions among people newly diagnosed with HIV in Manitoba, Canada from 2018 to 2021: a retrospective cohort study. *The Lancet Regional Health—Americas*, 36.
9. Israel, B. S., Belcher, A. M., & Ford, J. D. (2024). A harm reduction framework for integrated treatment of co-occurring opioid use disorder and trauma-related disorders. *Journal of Dual Diagnosis*, 20(1), 52-85.
10. Modani, A., Gurdak, K., Al Neyadi, L., Smith, M. E., Kelly, E., Thorning, H., ... & Pahwa, R. (2025). "Because I am a female": stigma and safety perspectives from racially/ethnically diverse women with serious mental illnesses. *Community mental health journal*, 61(3), 420-431.
11. Ahmad, N., Zainal, N., Shamsu, L. S., & Zamri, Z. H. (2025). Challenges of the Insanity Defence: Legal Perspectives on Mental Illness and Criminality in Brunei's Dual Legal System. *Manchester Journal of Transnational Islamic Law and Practice (MJTILP)*, 20(4), 150-177.
12. Butler, A., Nicholls, T. L., Samji, H., Fabian, S., & Lavergne, M. R. (2024). Mental health needs, substance use, and reincarceration: Population-level findings from a released prison cohort. *Criminal Justice and Behavior*, 51(7), 1054-1071.
13. Allen, K., Melendez-Torres, G. J., Ford, T., Bonell, C., & Berry, V. (2024). Experiences of current UK service provision for co-occurring parental domestic violence and abuse, mental ill-health, and substance misuse: A reflexive thematic analysis. *Children and Youth Services Review*, 158, 107449.
14. Apsley, H. B., Santos-Lozada, A. R., Gray, J., Hard, G., & Jones, A. A. (2024). Substance use treatment utilization among individuals with substance use disorders in the United States during the COVID-19 pandemic: Findings on the role of polysubstance use, criminal justice involvement, and mental illness from the National Survey on Drug Use and Health. *Substance Use: Research and Treatment*, 18, 29768357241259947.

15. Grewal, J., Kennedy, C. J., Mamman, R., Biagioni, J. B., Garcia-Barrera, M. A., & Schmidt, J. (2024). Understanding the barriers and facilitators of healthcare services for brain injury and concurrent mental health and substance use issues: a qualitative study. *BMC Health Services Research*, 24(1), 881.